Boston Sci Announces First Patient In Lotus™ TAVR Study



First Patient Enrolled in REPRISE II TAVR Clinical Trial to Evaluate the Safety and Performance of the Lotus™ Valve System (via PR Newswire)

NATICK, Mass., Oct. 10, 2012 /PRNewswire/ — Boston Scientific (NYSE: BSX) has enrolled the first patient in the REPRISE II clinical trial to evaluate the safety and performance of the Lotus™ Valve System in up to 120 patients with severe aortic valve disease.  This international, multi-center…